Tag Archives: case

ASCO: J&J pads case for new Erleada use with prostate cancer survival data

CHICAGO—Johnson & Johnson’s Erleada may be the follow-up to blockbuster Zytiga, but it’s also ready to go where its predecessor hasn’t gone before. Friday at the American Society of Clinical Oncology annual meeting, the New Jersey drugmaker rolled out results showing that adding Erleada to androgen deprivation therapy (ADT) cut the risk of death by 33%… Read More »